

EFFECT OF PHARMACOLOGIC AGENTS ON HUMAN KERATINOCYTE MITOSIS IN VITRO

III. Inhibition by Histamine and Methylated Analogs

ROBERT A. HARPER, PH.D., AND B. ALLEN FLAXMAN, M.D.*

*Temple University Health Sciences Center, Skin and Cancer Hospital of Philadelphia,
Philadelphia, Pennsylvania*

Keratinocytes from normal human skin were propagated in vitro. Histamine at 2×10^{-6} M inhibited mitosis 68%. The side-chain methylated analogs, *n*-methylhistamine and *n,n*-dimethylhistamine, produced an inhibitory response of 53 and 60%, respectively, at 1×10^{-6} M. The side-chain acetylated analog, *n*-acetylhistamine, did not elicit an inhibitory response in concentrations as high as 1×10^{-4} M. The ring-methylated analogs, 1-methylhistamine and 4-methylhistamine, produced some degree of mitotic inhibition at 1×10^{-4} M. When the H_1 -blocking agent, pyrilamine, or the H_2 -blocking agent, metiamide, was added in conjunction with histamine, the histamine-induced mitotic inhibition was abolished. These data indicate that human keratinocytes may possess receptors for histamine which could play a role in the regulation of human keratinocyte proliferation in vivo.

For decades histamine has been known to occur in the skin of mammals, mainly being located in mast cells of the dermis [1]. Much evidence indicates that histamine is a vasodilator involved in the pathogenesis of normal inflammatory responses and urticaria [2,3]. While a specific function for histamine in the physiologic behavior of epidermis has not been established, it was reported by Voorhees et al [4] that histamine in high concentrations (3.5×10^{-2} M) stimulated rat epidermal mitoses in vitro. Data were presented to support the hypothesis that the increased mitoses were due to a decrease in the concentration of intracellular cyclic AMP caused by histamine stimulation of the soluble epidermal cyclic AMP phosphodiesterase. These same authors later reported that histamine stimulation of rat epidermal mitosis may not be related to decreased cyclic AMP levels, but rather to increased synthesis of cyclic GMP [5].

In an earlier paper, we reported a contrary observation, namely that histamine inhibited the flow of human keratinocytes in vitro through the G_2 part of the cell cycle [6]. We have now verified that observation and, in addition, have shown that (1) neither precursor molecule nor breakdown products exhibit activity at comparable concentra-

tions of histamine, (2) the methylated side-chain derivatives retain full activity while the ring-methylated analogs do not, and (3) the block in G_2 may be mediated by histamine receptors.

MATERIALS AND METHODS

Normal human skin was obtained at surgery and primary outgrowth cultures of epidermal keratinocytes were made from explants according to a method described elsewhere [7]. Each explant gives rise to an outgrowing sheet of epithelial cells whose origin from epidermal keratinocytes has previously been demonstrated [7,8]. The cells are propagated in Eagle's minimum essential medium containing 10% fetal calf serum plus 100 U/ml each of penicillin, streptomycin, and mycostatin. After 7 to 10 days in culture approximately 200,000 cells are present in each dish. Cultures are maintained at 37°C in a high-humidity incubator in a mixture of 5% CO_2 in air.

To study the effect of histamine and related compounds on mitosis, a 4-hr in vitro metaphase collection assay was employed. Each compound was dissolved in culture fluid and an appropriate aliquot, never more than 1% of the total volume, was added to each dish to achieve the desired concentration. The metaphase arrest agent, Colcemid (3.5 μ g/ml) was added along with each test compound. After 4 hr the cultures were fixed in 10% buffered formalin, the explants removed from the coverslips, and the outgrowths stained in acid hematoxylin. Controls containing only Colcemid were run with each experiment. To determine the mitotic index (M.I.), the entire number of arrested metaphases is counted in each outgrowth. The total number of cells in each outgrowth is determined by the method of Chopra [9]. The M.I. is expressed as the number of arrested metaphases per 1000 cells. Since the assay covers only a 4-hr period and G_2 is known to be at least 7 hr in this system [10], any effect on the M.I. is probably due to inhibition in G_2 . For each dish the M.I. was obtained for each outgrowth and then the mean M.I. and standard deviation were calculated. The

Manuscript received April 4, 1975; in revised form May 19, 1975; accepted for publication June 10, 1975.

This work was supported by Grant CA 11536 from the National Cancer Institute.

* Present address: Brown University and Miriam Hospital, Subsection of Dermatology, Section of Medicine, Providence, Rhode Island 02912.

Reprints requests to: Dr. R. A. Harper, Temple University Health Sciences Center, Skin and Cancer Hospital of Philadelphia, Philadelphia, Pennsylvania 19140.

statistical significance of the data obtained for each experiment was evaluated by using Student's *t*-test for unpaired data. The data in the Tables represent one experiment for each concentration listed. However, for each compound tested at the various concentrations, two or more experiments were carried out using skin obtained from different patients. Due to normal fluctuations in donor skin metabolism, control values vary from experiment to experiment. However, the final results (% inhibition) were consistent within the experimental error of the biologic assay. To study the effect of histamine-blocking agents, the blocking agent was added to the culture $\frac{1}{2}$ hr before addition of the amine and Colcemid for the usual 4 hr.

Histamine dihydrochloride was purchased from Sigma Chemical Co. (St. Louis, Mo.). Pyrilamine and metiamide were gifts from Dr. Marshall Guthrie (Smith, Kline and French Laboratories, Philadelphia, Pa.); *n*-methylhistamine, *n,n*-dimethylhistamine, and 4-methylhistamine were kindly supplied to us by Dr. W. A. M. Duncan (Smith, Kline and French Laboratories, England); and 1-methylhistamine and *n*-acetylhistamine were purchased from Calbiochem. (San Diego, Cal.).

RESULTS

At concentrations ranging from 2×10^{-2} to 2×10^{-6} M, histamine substantially inhibited the progression of cells through G_2 (Tab. I). The maximum inhibition that could be obtained was 68% at 2×10^{-6} M. The level of inhibition dropped to zero at 2×10^{-8} M. Various imidazole-related compounds had no effect on inhibiting mitosis at concentrations comparable to that of histamine (Tab. II). Imidazole itself did inhibit mitosis at 1×10^{-3} M, but this activity dropped to zero at 1×10^{-4} M.

The side-chain methyl derivatives, *n*-methylhistamine and *n,n*-dimethylhistamine, produced mitotic inhibition comparable to histamine (Tab. III). It would appear that the two side-chain derivatives produce comparable inhibition of cells in G_2 . The acetylated side-chain analog, *n*-acetyl-

histamine, produced no mitotic inhibition even at concentrations as high as 1×10^{-4} M. The ring-methylated derivatives exhibit some degree of activity of 1×10^{-4} M; however, this decreases to a residual level at 1×10^{-5} M.

At a concentration of 1×10^{-6} M, the H_1 -blocking agent, pyrilamine, and the H_2 -blocking agent, metiamide, exhibited no mitotic inhibition. When either of these blocking agents was added in conjunction with histamine, the histamine-induced inhibition was effectively abolished (Tab. IV).

DISCUSSION

There was a striking difference in response to histamine between the rat epidermal in vitro system and our human keratinocyte in vitro system. As mentioned previously, in rat epidermis, histamine *stimulates* mitosis either by acting on the cyclic AMP or cyclic GMP system [4,5]. However, in our human cell system, histamine exhibited strong *inhibition* of mitosis in concentrations from 2×10^{-2} M to 2×10^{-6} M. The reason for this "species" difference may be related to the experimental models employed. We are measuring responses of human keratinocytes propagated in vitro, whereas Voorhees et al [4] used "whole rat skin" in organ culture. The dermis in the latter system may be influencing the epidermal response to histamine. A species variation in the molecular structure of the receptor could also explain the different responses. It seems quite probable that histamine in our cell system is acting via the adenylyl cyclase system [11-15]. More specifically, in human skin, histamine has been found to raise the level of cyclic AMP (K. Halprin, personal communication). Based on our previous studies [16] an increase in intracellular cyclic AMP would inhibit the flow of cells through G_2 . However, the possibility that cyclic GMP levels are modulated by this amine cannot be overlooked.

We were very much interested in determining whether compounds containing the imidazole moiety could elicit a mitotic inhibitory response.

TABLE I. Effect of histamine on human keratinocyte mitosis in vitro^a

Histamine Conc (M)	M.I. ^b ± SD		Percent Inhibition
	Control	Test	
2×10^{-2}	19.5 ± 5.2	6.5 ± 2.6 (p < 0.001)	67
2×10^{-5}	20.2 ± 2.7	7.4 ± 0.8 (p < 0.001)	63
2×10^{-6}	20.2 ± 2.7	6.4 ± 3.5 (p < 0.001)	68
2×10^{-7}	20.2 ± 2.7	14.7 ± 1.1 (p < 0.005)	27
2×10^{-8}	20.2 ± 2.7	22.8 ± 4.0 (p > 0.150)	0 (+12)

^a For normal skin p values < 0.05 are considered to be statistically significant.

^b M.I. (mitotic index) is the proportion of arrested metaphases per 1000 cells accumulated during the 4-hr period following Colcemid treatment.

TABLE II. Effect of imidazole compounds on human keratinocyte mitosis in vitro

Compound	Conc (M)	M.I. ± SD		Percent Inhibition
		Control	Test	
Histidine	1×10^{-3}	21.9 ± 2.3	17.2 ± 3.1 (p < 0.025)	21
Urocanic acid	1×10^{-3}	33.5 ± 2.5	30.8 ± 1.3 (p < 0.050)	8
Imidazole acetate	1×10^{-3}	25.8 ± 1.0	20.0 ± 2.4 (p < 0.010)	22
	1×10^{-4}	25.8 ± 1.0	25.5 ± 1.4 (p > 0.350)	0
Imidazole	1×10^{-3}	25.8 ± 1.0	15.2 ± 1.5 (p < 0.001)	41
	1×10^{-4}	25.8 ± 1.0	25.2 ± 3.4 (p > 0.350)	0

TABLE III. Effect of histamine analogs on human keratinocyte mitosis in vitro

Amine	Conc (M)	M.I. ± SD		Percent Inhibition
		Control	Test	
<i>n</i> -Methylhistamine	1 × 10 ⁻⁴	37.0 ± 4.6	6.7 ± 0.8 (p < 0.001)	82
	1 × 10 ⁻⁵	37.0 ± 4.6	14.2 ± 1.6 (p < 0.001)	62
	1 × 10 ⁻⁶	23.8 ± 0.3	11.2 ± 1.4 (p < 0.001)	53
	1 × 10 ⁻⁷	21.5 ± 0.7	21.6 ± 1.6 (p > 0.400)	0
<i>n,n</i> -Dimethylhistamine	1 × 10 ⁻⁴	37.0 ± 4.6	12.4 ± 2.9 (p < 0.001)	66
	1 × 10 ⁻⁵	37.0 ± 4.6	15.9 ± 1.0 (p < 0.001)	57
	1 × 10 ⁻⁶	23.8 ± 0.3	9.6 ± 1.0 (p < 0.001)	60
	1 × 10 ⁻⁷	21.5 ± 0.7	20.7 ± 1.0 (p > 0.100)	4
<i>n</i> -Acetylhistamine	1 × 10 ⁻⁴	37.0 ± 4.6	41.2 ± 7.5 (p > 0.150)	0 (+11)
1-Methylhistamine	1 × 10 ⁻⁴	35.8 ± 0.4	22.6 ± 1.8 (p < 0.001)	37
	1 × 10 ⁻⁵	21.5 ± 0.7	18.6 ± 2.9 (p > 0.050)	14
4-Methylhistamine	1 × 10 ⁻⁴	35.8 ± 0.4	21.5 ± 1.7 (p < 0.001)	40
	1 × 10 ⁻⁵	23.8 ± 0.3	20.3 ± 2.6 (p < 0.050)	15

TABLE IV. Effect of H₁- and H₂-blocking agents on histamine-induced mitotic inhibition in human keratinocytes in vitro

Compound	Conc (M)	M.I. ± SD		Percent Inhibition
		Control	Test	
Histamine	2 × 10 ⁻⁶	23.6 ± 2.4	12.5 ± 1.0 (p < 0.001)	47
Pyrilamine ^a	1 × 10 ⁻⁶	23.6 ± 2.4	23.4 ± 2.9 (p > 0.450)	0
Metiamide	1 × 10 ⁻⁶	23.6 ± 2.4	21.4 ± 2.0 (p > 0.100)	9
Histamine + Pyrilamine	2 × 10 ⁻⁶	23.6 ± 2.4	22.1 ± 2.1 (p > 0.200)	6
Histamine + Metiamide	2 × 10 ⁻⁶	23.6 ± 2.4	19.7 ± 4.2 (p > 0.050)	16
	1 × 10 ⁻⁶			

^a Blocking agents were added 1/2 hr before histamine.

This was especially true since histidine metabolism is very active in the epidermis. Our results showed that neither histidine, the precursor to histamine, nor one of its breakdown products, imidazole acetate, affected our cells. Urocanic acid which is normally found in large quantities in the epidermis [17] had no effect on mitosis. Imidazole did have a suppressive effect at 1 × 10⁻³ M. Since

imidazole can stimulate cyclic AMP phosphodiesterase activity in vitro [18] leading to a decrease in cyclic AMP, such an effect should lead to an increase in mitosis, not a decrease. The explanation for the observed effect remains unclear.

It is important to note the activities of the various methylated analogs of histamine. Our data would support the conclusion that side-chain methylation preserves the activity of the histamine molecule. This is compatible with the in vivo data in other mammalian tissues which suggest that the products of side-chain methylation are as active or even more active than histamine [14]. On the other hand, acetylation of the side-chain terminal nitrogen abolished all activity. It would be conceivable that in skin in vivo the amount of histamine available to the epidermis could be controlled conveniently by acetylation. And indeed, one of the breakdown products of histamine in man is *n*-acetylhistamine. It would be of interest to see whether human skin, particularly the epidermis, has any of the necessary enzymes to degrade or inactivate histamine, and if any of these enzymes are elevated in hyperproliferative skin diseases such as psoriasis.

It was of some surprise to find evidence that human keratinocytes, at least in vitro, may have specific receptor sites for histamine. Since pyrilamine and metiamide blocked the action of histamine, no clear-cut distinction between H₁ and H₂

receptors can be made at this time. Studies are under way to differentiate the histamine receptor from the β -adrenergic receptor, since we reported earlier that human keratinocytes *in vitro* may contain β -receptors [19]. The existence of specific histamine receptor sites on keratinocytes suggests that histamine may play a regulatory role in control of epidermal mitosis.

We would like to thank Drs. L. I. Goldman and W. Maier for obtaining skin used in this study, Mrs Barbara Kain and Miss Sharon Shoemaker for expert technical assistance, and Miss Rose Di Bella for typing of the manuscript.

REFERENCES

1. Montagna W: The Structure and Function of Skin. Second edition. New York, Academic, 1972
2. Parish WE: Effectors of immunologic responses: their expression and modes of action in skin. Immunology and The Skin, Advances in Biology of Skin, vol XI. Edited by W Montagna, RE Billingham. New York, Appleton-Century-Crofts, 1971, pp 1-28
3. Willoughby DA: Some views on the pathogenesis of inflammation. The Dermis, Advances in Biology of Skin, vol X. Edited by W Montagna, PJ Bentley, RL Dobson. New York, Appleton-Century-Crofts, 1970, pp 221-230
4. Voorhees JJ, Duell EA, Bass LJ, Powell JA, Harrell ER: The cyclic AMP system in normal and psoriatic epidermis. *J Invest Dermatol* 59:114-120, 1972
5. Voorhees JJ, Kelsey W, Stawiski M, Smith E, Duell E, Haddox M, Goldberg N: Increased cyclic GMP and decreased Cyclic AMP levels in the rapidly proliferating epithelium of psoriasis. The Role of Cyclic Nucleotides in Carcinogenesis, Miami Winter Symposium, vol 6. Edited by J Schultz, HG Gratzner. New York, Academic, 1973, pp 325-367
6. Harper RA, Flaxman BA, Chopra DP: Mitotic response of normal and psoriatic keratinocytes *in vitro* to compounds known to affect intracellular cyclic AMP. *J Invest Dermatol* 62:384-387, 1974
7. Flaxman BA, Lutzner MA, Van Scott EJ: Cell maturation and tissue organization in epithelial outgrowths from skin and buccal mucosa *in vitro*. *J Invest Dermatol* 49:322-332, 1967
8. Flaxman BA: Replication and differentiation *in vitro* of epidermal cells from normal human skin and from benign (psoriasis) and malignant (basal cell cancer) hyperplasia. *In Vitro* 8:237-256, 1972
9. Chopra DP: The control of cell division in the embryonic and mature amphibian kidney. Ph.D. thesis. University of Newcastle upon Tyne, England, 1971
10. Chopra DP, Flaxman BA: Human epidermal cell cycle *in vitro*. *Br J Dermatol* 87:13-17, 1972
11. Kakiuchi S, Rall TW: The influence of chemical agents on the accumulation of adenosine 3',5'-phosphate in slices of rabbit cerebellum. *Mol Pharmacol* 4:367-378, 1968
12. Nakajima S, Hirschowitz BI, Sachs G: Studies on adenyl cyclase in necturus gastric mucosa. *Arch Biochem Biophys* 143:123-126, 1971
13. Klein I, Levey GS: Activation of myocardial adenyl cyclase by histamine in guinea pig, cat and human heart. *J Clin Invest* 50:1012-1015, 1971
14. Dousa TP, Code CF: Effect of histamine and its methyl derivatives on cyclic AMP metabolism in gastric mucosa and its blockade by an H_2 receptor antagonist. *J Clin Invest* 53:334-337, 1974
15. Lindl T, Cramer H: Formation, accumulation and release of adenosine 3',5'-monophosphate induced by histamine in the superior cervical ganglion of the rat *in vitro*. *Biochim Biophys Acta* 343:182-191, 1974
16. Harper RA, Flaxman BA, Chopra DP: Effect of pharmacological agents on human keratinocyte mitosis *in vitro*. I. Inhibition by adenine nucleotides. *Proc Soc Exp Biol Med* 146:1032-1036, 1974
17. Baden HP, Pathak MA: The metabolism and function of urocanic acid in skin. *J Invest Dermatol* 48:11-17, 1967
18. Mik N, Yoshida H: Purification and properties of cyclic AMP phosphodiesterase from rat brain. *Biochim Biophys Acta* 268:166-174, 1972
19. Harper RA, Flaxman BA: Effect of pharmacological agents on human keratinocyte mitosis *in vitro*. II. Inhibition by catecholamines. *J Cell Physiol* (in press) 1975